NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare... Show more
NEUE broke above its upper Bollinger Band on June 27, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 23 similar instances where the stock broke above the upper band. In of the 23 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on July 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NEUE as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NEUE turned negative on July 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 28 similar instances when the indicator turned negative. In of the 28 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 49 cases where NEUE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
NEUE moved above its 50-day moving average on July 11, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NEUE advanced for three days, in of 192 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 73 cases where NEUE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NEUE's P/B Ratio (0.000) is slightly lower than the industry average of (3.063). NEUE's P/E Ratio (0.000) is considerably lower than the industry average of (17.509). NEUE's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.089). NEUE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). NEUE's P/S Ratio (0.043) is slightly lower than the industry average of (0.684).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NEUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry ManagedHealthCare
A.I.dvisor tells us that NEUE and CLOV have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NEUE and CLOV's prices will move in lockstep.
Ticker / NAME | Correlation To NEUE | 1D Price Change % | ||
---|---|---|---|---|
NEUE | 100% | -0.15% | ||
CLOV - NEUE | 24% Poorly correlated | -0.33% | ||
CVS - NEUE | 21% Poorly correlated | -0.78% | ||
UNH - NEUE | 21% Poorly correlated | -1.51% | ||
CI - NEUE | 21% Poorly correlated | -2.47% | ||
OSCR - NEUE | 21% Poorly correlated | -9.64% | ||
More |